High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma

Detalhes bibliográficos
Autor(a) principal: Alves, Bárbara
Data de Publicação: 2023
Outros Autores: Peixoto, Joana, Macedo, Sofia, Pinheiro, Jorge, Carvalho, Bruno, Soares, Paula, Lima, Jorge, Lima, Raquel T.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.22/23087
Resumo: Glioblastoma (GB) is a deadly tumor that demands for relevant biomarkers, particularly regarding patients’ response to treatment. MMP-2, MMP-9, VEGFA, and YKL40 are important molecules, given their implication in the infiltrative and angiogenic phenotype of GBs. The purpose of this study was to assess the relationship between the expression of MMP-2, MMP-9, VEGFA, and YKL40 in GB tissues and the patients’ response to temozolomide (first-line treatment) or bevacizumab (second-line treatment). Our results showed that increased VEGFA is significantly associated with an improved response to bevacizumab, while having no correlation with the response to temozolomide. Additionally, YKL40 expression may also be important regarding information about the extent of antiangiogenic treatment in GB patients.
id RCAP_48f900331f88066131261bd5f00af912
oai_identifier_str oai:recipp.ipp.pt:10400.22/23087
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent GlioblastomaGlioblastomaSecretomeBiomarkersImmunohistochemistryVEGFAYKL40MMP-2MMP-9Glioblastoma (GB) is a deadly tumor that demands for relevant biomarkers, particularly regarding patients’ response to treatment. MMP-2, MMP-9, VEGFA, and YKL40 are important molecules, given their implication in the infiltrative and angiogenic phenotype of GBs. The purpose of this study was to assess the relationship between the expression of MMP-2, MMP-9, VEGFA, and YKL40 in GB tissues and the patients’ response to temozolomide (first-line treatment) or bevacizumab (second-line treatment). Our results showed that increased VEGFA is significantly associated with an improved response to bevacizumab, while having no correlation with the response to temozolomide. Additionally, YKL40 expression may also be important regarding information about the extent of antiangiogenic treatment in GB patients.MDPIRepositório Científico do Instituto Politécnico do PortoAlves, BárbaraPeixoto, JoanaMacedo, SofiaPinheiro, JorgeCarvalho, BrunoSoares, PaulaLima, JorgeLima, Raquel T.2023-06-07T10:18:41Z2023-04-072023-04-07T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/23087engAlves, B., Peixoto, J., Macedo, S., Pinheiro, J., Carvalho, B., Soares, P., Lima, J., & Lima, R. T. (2023). High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. Cancers, 15(8), 2196. https://doi.org/10.3390/cancers150821962072-669410.3390/cancers15082196info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-06-14T01:46:43Zoai:recipp.ipp.pt:10400.22/23087Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:00:24.339861Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
title High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
spellingShingle High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
Alves, Bárbara
Glioblastoma
Secretome
Biomarkers
Immunohistochemistry
VEGFA
YKL40
MMP-2
MMP-9
title_short High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
title_full High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
title_fullStr High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
title_full_unstemmed High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
title_sort High VEGFA expression Is associated with improved progression-free survival after Bevacizumab treatment in recurrent Glioblastoma
author Alves, Bárbara
author_facet Alves, Bárbara
Peixoto, Joana
Macedo, Sofia
Pinheiro, Jorge
Carvalho, Bruno
Soares, Paula
Lima, Jorge
Lima, Raquel T.
author_role author
author2 Peixoto, Joana
Macedo, Sofia
Pinheiro, Jorge
Carvalho, Bruno
Soares, Paula
Lima, Jorge
Lima, Raquel T.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Politécnico do Porto
dc.contributor.author.fl_str_mv Alves, Bárbara
Peixoto, Joana
Macedo, Sofia
Pinheiro, Jorge
Carvalho, Bruno
Soares, Paula
Lima, Jorge
Lima, Raquel T.
dc.subject.por.fl_str_mv Glioblastoma
Secretome
Biomarkers
Immunohistochemistry
VEGFA
YKL40
MMP-2
MMP-9
topic Glioblastoma
Secretome
Biomarkers
Immunohistochemistry
VEGFA
YKL40
MMP-2
MMP-9
description Glioblastoma (GB) is a deadly tumor that demands for relevant biomarkers, particularly regarding patients’ response to treatment. MMP-2, MMP-9, VEGFA, and YKL40 are important molecules, given their implication in the infiltrative and angiogenic phenotype of GBs. The purpose of this study was to assess the relationship between the expression of MMP-2, MMP-9, VEGFA, and YKL40 in GB tissues and the patients’ response to temozolomide (first-line treatment) or bevacizumab (second-line treatment). Our results showed that increased VEGFA is significantly associated with an improved response to bevacizumab, while having no correlation with the response to temozolomide. Additionally, YKL40 expression may also be important regarding information about the extent of antiangiogenic treatment in GB patients.
publishDate 2023
dc.date.none.fl_str_mv 2023-06-07T10:18:41Z
2023-04-07
2023-04-07T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.22/23087
url http://hdl.handle.net/10400.22/23087
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Alves, B., Peixoto, J., Macedo, S., Pinheiro, J., Carvalho, B., Soares, P., Lima, J., & Lima, R. T. (2023). High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. Cancers, 15(8), 2196. https://doi.org/10.3390/cancers15082196
2072-6694
10.3390/cancers15082196
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131673246302208

Registros relacionados